Who may be eligible for the A Registry for People With T-cell Lymphoma trial?

Inclusion Criteria: * Written informed consent * Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy. * Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines): * T-cell prolymphocytic leukemia * T-cell large granular lymphocytic leukemia * Chronic lymphoproliferative disorder of NK cells * Aggressive NK-cell leukemia * Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood * Chronic active EBV infection of T- and NK-cell type, systemic form * Hydroa vacciniforme-like lymphoproliferative disorder * Adult T-cell leukemia/lymphoma * Extranodal NK/T-cell lymphoma, nasal type * Enteropathy-associated T-cell lymphoma * Monomorphic epitheliotropic intestinal T-cell lymphoma * Intestinal T-cell lymphoma, not otherwise specified (NOS) * Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract * Hepatosplenic T-cell lymphoma * Subcutaneous panniculitis-like T-cell lymphoma * Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy) * Sézary syndrome * Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy) * Primary cutaneous Gamma-Delta T-cell lymphoma * Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma * Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy) * Peripheral T-cell lymphoma, not otherwise specified * Angioimmunoblastic T-cell lymphoma * Follicular T-cell lymphoma * Nodal peripheral T-cell lymphoma with TFH phenotype * Anaplastic large cell lymphoma, ALK-positive * Anaplastic large cell lymphoma, ALK-negative * Breast-implant associated anaplastic large cell lymphoma. * NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy. Exclusion Criteria: * Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy. * Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.

ClinicalTrials.gov record NCT05978141

A Registry for People With T-cell Lymphoma

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Sep 17, 2026

The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens

About this page. This page shows the study's official ClinicalTrials.gov record ↗, with added help to make it easier to understand. We explain medical terms, highlight key details in plain language, and suggest questions you may want to ask the study team.

The record is periodically copied from ClinicalTrials.gov and may lag behind changes. AI summaries are checked by software, not a clinician.Read moreShow less

The official record is written by the study sponsor and published on ClinicalTrials.gov. It may not always reflect the latest changes. Before making any decisions, please confirm important information with the study team and your own healthcare team.

Where you see "AI summary", AI was used to create a plain-language explanation and software checked it against the source. It has not been reviewed by a clinician, so it may contain mistakes or leave out important details.

StatusRecruitingThe study is currently enrolling participants. Only the study team can say whether a particular person can join.

Study typeObservationalA study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.

SexAll

LocationUnited States

AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This is a prospective registry that will gather clinical information and matched tumor specimens from people with T‑cell or NK‑cell lymphomas. Participation typically involves providing medical data from care and, optionally, blood and nail samples for biobanking. The registry will follow participants and store linked clinical and pathology data for up to 10 years to support research.

What it is studying. To create a linked database of clinical records and matched tumor specimens so researchers can study disease features, treatments, and outcomes in T‑cell and NK‑cell lymphomas.

What the researchers hope to learn. To develop and populate a secure database of patients with T‑cell and NK‑cell lymphomas that contains curated clinical characteristics, treatment information, outcomes, and matched pathological biospecimens for future research.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

Interventions being studied

Being studied in this trial does not mean the treatment or procedure is approved or available for this condition.

Other: Optional Blood Sample and Nail Sample

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

Written informed consent
Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.
Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):
T-cell prolymphocytic leukemia
T-cell large granular lymphocytic leukemia
Chronic lymphoproliferative disorder of NK cells
Aggressive NK-cell leukemia
Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
Chronic active EBV infection of T- and NK-cell type, systemic form
Hydroa vacciniforme-like lymphoproliferative disorder
Adult T-cell leukemia/lymphoma
Extranodal NK/T-cell lymphoma, nasal type
Enteropathy-associated T-cell lymphoma
Monomorphic epitheliotropic intestinal T-cell lymphoma
Intestinal T-cell lymphoma, not otherwise specified (NOS)
Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
Hepatosplenic T-cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma
Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
Sézary syndrome
Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
Primary cutaneous Gamma-Delta T-cell lymphoma
Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
Peripheral T-cell lymphoma, not otherwise specified
Angioimmunoblastic T-cell lymphoma
Follicular T-cell lymphoma
Nodal peripheral T-cell lymphoma with TFH phenotype
Anaplastic large cell lymphoma, ALK-positive
Anaplastic large cell lymphoma, ALK-negative
Breast-implant associated anaplastic large cell lymphoma.
NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.

Exclusion criteria

Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.

Study description and what participation involves

The registry record has no detailed description beyond the summary above.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

After giving informed consent, participants provide clinical information and treatment/outcome data and supply a tumor specimen (either existing archival tissue or a fresh biopsy). They may optionally give blood and nail samples for biobanking and future research. The treating team will collect follow‑up data and measure response as clinically appropriate; data and specimens are stored and linked in the repository (target duration up to 10 years).

How the study is structured. An observational, prospective registry (cohort). Clinical information and pathology specimens are collected and stored; participation can include optional research blood and nail samples. Participants are followed and data curated over a target period of up to 10 years.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
The listed sites are in United States. Is any of them reachable for me, and does the study help with travel?
Which of the eligibility criteria would need to be checked with tests before I could join?

More on large granular lymphocytic leukemia

Clinical trials16 trials listed for large granular lymphocytic leukemiaEvery trial the registry lists for large granular lymphocytic leukemia, with recruitment status, phase and sites, updated from ClinicalTrials.gov.See all trials →Research updatesWhat changed in large granular lymphocytic leukemia researchLatest monthly update: September 2026. Includes: Treatment response reports. New research summarized each month in plain language, with links to every source paper.Read the latest update →

Important dates

Study start: Jul 27, 2023
Primary completion: Jul 27, 2030 (estimated)
Study completion: Jul 27, 2030 (estimated)
Target enrollment: 1000 participants (estimated)
Last updated on registry: May 20, 2026
Data verified: Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor: Memorial Sloan Kettering Cancer Center

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Steven Horwitz, MD 📞 646-608-2680 ✉ horwitzs@MSKCC.ORG
Alison Moskowitz, MD 📞 646-608-3726 ✉ moskowia@mskcc.org

Participating sites (26)

City of Hope Cancer Center (Data collection only)Not Yet Recruiting
Duarte, California, 91010 · United States
- Jasmine Zain, MD · 626-359-8111
UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only)Not Yet Recruiting
San Diego, California, 92103 · United States
- Aaron Goodman, MD · 858-822-6100
University of California San Francisco (Data collection only)Not Yet Recruiting
San Francisco, California, 94143 · United States
- Weiyun Ai, MD · 415-353-2421
Stanford University Medical Center (Data collection only)Not Yet Recruiting
Stanford, California, 94305-5408 · United States
- Michael Khodadoust, MD · 650-725-5071
University of Colorado (Data Collection Only)Not Yet Recruiting
Aurora, Colorado, 80045 · United States
- Bradley Haverkos, MD · 212-639-3983
Yale University (Data Collection Only)Not Yet Recruiting
New Haven, Connecticut, 06511 · United States
- Francine Foss, MD · 203-200-4363
University of Miami (Data Collection Only)Not Yet Recruiting
Miami, Florida, 33136 · United States
- Jonathan Schatz, MD · 305-243-5302
Moffitt Cancer Center (Data Collection Only)Not Yet Recruiting
Tampa, Florida, 33612 · United States
- Lubomir Sokol, MD, PhD · 888-663-3488
Emory University (Data Collection Only)Not Yet Recruiting
Atlanta, Georgia, 30322 · United States
- Pamela Allen, MD, MSc · 404-778-0519
Northwestern Medicine (Data Collection)Not Yet Recruiting
Chicago, Illinois, 60611 · United States
- Jaehyuk Choi, MD, PhD · 312-695-8106

Terms used on this page · explanations by MedicalUpdates.ai

registry: An organised collection of information about people with a particular condition, gathered over time for research. Joining a registry usually means sharing medical information, not receiving a treatment.
Written informed consent: The process of explaining a study, including its risks and what participation involves, so that a person can decide freely whether to take part. Consent is usually documented in writing, and a participant can choose to leave the study later.
biopsy: Removal of a small piece of tissue so it can be examined under a microscope. 'Biopsy-proven' or 'histologically confirmed' means the diagnosis was confirmed by examining tissue under a microscope.
follow-up: The period after treatment or enrolment during which participants are observed or contacted, for example to record side effects or outcomes.
clinical trial: A study in which researchers assign participants to one or more interventions, such as a drug, procedure, device, behavioural programme or other approach, to measure their effects.
enrollment: The number of participants a study plans to include, or has included. 'Estimated' means the planned number; 'actual' means the number who joined.
Inclusion Criteria: The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
Exclusion Criteria: The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials